Want full text access to this journal?
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
Xiao Xu, Haiqun Lin, Jason D Wright, Cary P Gross, Francis P Boscoe, Lindsey M Hutchison, Peter E Schwartz, Vrunda B Desai
PURPOSE: Despite concerns that power morcellation may adversely affect prognosis of patients with occult uterine cancer, empirical evidence has been limited and inconclusive. In this study, we aimed to determine whether uncontained power morcellation at the time of hysterectomy or myomectomy is associated with increased mortality risk in women with occult uterine cancer. METHODS: By linking statewide hospital discharge records with cancer registry data in New York, we identified 843 women with occult endometrial carcinoma and 334 women with occult uterine sarcoma who underwent a hysterectomy or myomectomy for presumed benign indications during the period October 1, 2003, through December 31, 2013...
September 16, 2019: Journal of Clinical Oncology
#2
Ursula A Matulonis, Lydia Walder, Trine J Nøttrup, Paul Bessette, Sven Mahner, Marta Gil-Martin, Elsa Kalbacher, Jonathan A Ledermann, Robert M Wenham, Kathrine Woie, Susie Lau, Frederik Marmé, Antonio Casado Herraez, Anne-Claire Hardy-Bessard, Susana Banerjee, Gabriel Lindahl, Benedict Benigno, Joseph Buscema, Karin Travers, Holly Guy, Mansoor R Mirza
PURPOSE: This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer. PATIENTS AND METHODS: Mean progression-free survival (PFS) was estimated for niraparib and RS by fitting parametric survival distributions to Kaplan-Meier data for 553 patients with recurrent ovarian cancer who were enrolled in the phase III ENGOT-OV16/NOVA trial. Patients were categorized according to the presence or absence of a germline BRCA mutation-g BRCA mut and non-g BRCA mut cohorts...
September 16, 2019: Journal of Clinical Oncology
#3
Hyun-Ah Kim, Jong Won Lee, Seok Jin Nam, Byeong-Woo Park, Seock-Ah Im, Eun Sook Lee, Yong Sik Jung, Jung Han Yoon, Sung Soo Kang, Soo-Jung Lee, Kyong Hwa Park, Joon Jeong, Se-Heon Cho, Sung Yong Kim, Lee Su Kim, Byung-In Moon, Min Hyuk Lee, Tae Hyun Kim, Chanheun Park, Sung Hoo Jung, Geumhee Gwak, Jeryong Kim, Sun Hee Kang, Young Woo Jin, Hee Jeong Kim, Se-Hwan Han, Wonshik Han, Min Hee Hur, Woo Chul Noh
PURPOSE: The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to TAM in patients with hormone receptor-positive breast cancer who remain in a premenopausal state or resume ovarian function after chemotherapy. PATIENTS AND METHODS: We enrolled 1,483 premenopausal women (age ≤ 45 years) with estrogen receptor-positive breast cancer treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy...
September 16, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#4
Arun Kumar Goel, Vaishali Zamre, Prekshi Chaudhary, Gopal Sharma, Dinesh Singh
No abstract text is available yet for this article.
September 13, 2019: Journal of Clinical Oncology
#5
Sara M Tolaney, Eric P Winer
No abstract text is available yet for this article.
September 13, 2019: Journal of Clinical Oncology
#6
Filippo Pietrantonio, Rosalba Miceli, Alessandra Raimondi, Young Woo Kim, Won Ki Kang, Ruth E Langley, Yoon Young Choi, Kyoung-Mee Kim, Matthew Guy Nankivell, Federica Morano, Andrew Wotherspoon, Nicola Valeri, Myeong-Cherl Kook, Ji Yeong An, Heike I Grabsch, Giovanni Fucà, Sung Hoon Noh, Tae Sung Sohn, Sung Kim, Maria Di Bartolomeo, David Cunningham, Jeeyun Lee, Jae-Ho Cheong, Elizabeth Catherine Smyth
PURPOSE: In the CLASSIC and MAGIC trials, microsatellite instability (MSI)-high status was a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant chemotherapy in resectable gastric cancer (GC). Given the low prevalence of MSI-high status in GC and its association with other positive prognostic variables, large data sets are needed to draw robust evidence of its prognostic/predictive value. PATIENTS AND METHODS: We performed a multinational, individual-patient-data meta-analysis of the prognostic/predictive role of MSI in patients with resectable GC enrolled in the MAGIC, CLASSIC, ARTIST, and ITACA-S trials...
September 12, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#7
Lori A Spoozak
No abstract text is available yet for this article.
September 12, 2019: Journal of Clinical Oncology
#8
Jean Donadieu, Islam Amine Larabi, Mathilde Tardieu, Johannes Visser, Caroline Hutter, Elena Sieni, Nabil Kabbara, Mohamed Barkaoui, Jean Miron, François Chalard, Paul Milne, Julien Haroche, Fleur Cohen, Zofia Hélias-Rodzewicz, Nicolas Simon, Mathilde Jehanne, Alexandra Kolenova, Anne Pagnier, Nathalie Aladjidi, Pascale Schneider, Geneviève Plat, Anne Lutun, Anne Sonntagbauer, Thomas Lehrnbecher, Alina Ferster, Viktoria Efremova, Martina Ahlmann, Laurence Blanc, James Nicholson, Anne Lambilliote, Houda Boudiaf, Andrej Lissat, Karel Svojgr, Fanette Bernard, Sarah Elitzur, Michal Golan, Dmitriy Evseev, Michael Maschan, Ahmed Idbaih, Olga Slater, Milen Minkov, Valerie Taly, Matthew Collin, Jean-Claude Alvarez, Jean-François Emile, Sébastien Héritier
PURPOSE: Off-label use of vemurafenib (VMF) to treat BRAFV600E mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. PATIENTS AND METHODS: Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were classified according to risk organ involvement: liver, spleen, and/or blood cytopenia. The main evaluation criteria were adverse events (Common Terminology Criteria for Adverse Events [version 4.3]) and therapeutic responses according to Disease Activity Score...
September 12, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#9
Leo Mascarenhas, Yueh-Yun Chi, Pooja Hingorani, James R Anderson, Elizabeth R Lyden, David A Rodeberg, Daniel J Indelicato, Simon C Kao, Roshni Dasgupta, Sheri L Spunt, William H Meyer, Douglas S Hawkins
PURPOSE: The primary aim of this clinical trial was to prioritize bevacizumab or temsirolimus for additional investigation in rhabdomyosarcoma (RMS) when administered in combination with cytotoxic chemotherapy to patients with RMS in first relapse with unfavorable prognosis. PATIENTS AND METHODS: Patients were randomly assigned to receive bevacizumab on day 1 or temsirolimus on days 1, 8, and 15 of each 21-day treatment cycle, together with vinorelbine on days 1 and 8, and cyclophosphamide on day 1 for a maximum of 12 cycles...
September 12, 2019: Journal of Clinical Oncology
#10
Mohamad Jawhar, Juliana Schwaab, Iván Álvarez-Twose, Khalid Shoumariyeh, Nicole Naumann, Johannes Lübke, Cecelia Perkins, Javier I Muñoz-González, Manja Meggendorfer, Vanessa Kennedy, Georgia Metzgeroth, Alice Fabarius, Dietmar Pfeifer, Karl Sotlar, Hans-Peter Horny, Nikolas von Bubnoff, Torsten Haferlach, Nicholas C P Cross, Wolf-Karsten Hofmann, Wolfgang R Sperr, Andrés C García-Montero, Peter Valent, Jason Gotlib, Alberto Orfao, Andreas Reiter
PURPOSE: To develop a risk score for patients with advanced systemic mastocytosis (AdvSM) that integrates clinical and mutation characteristics. PATIENTS AND METHODS: The study included 383 patients with AdvSM from the German Registry on Disorders of Eosinophils and Mast Cells (training set; n = 231) and several centers for mastocytosis in the United States and Europe, all within the European Competence Network on Mastocytosis (validation set; n = 152). A Cox multivariable model was used to select variables that were predictive of overall survival (OS)...
September 11, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#11
David J VanderWeele, Emmanuel S Antonarakis, Michael A Carducci, Robert Dreicer, Karim Fizazi, Silke Gillessen, Celeste S Higano, Alicia K Morgans, Daniel P Petrylak, Christopher J Sweeney, Maha Hussain
No abstract text is available yet for this article.
September 10, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#12
Michael Fuchs, Helen Goergen, Carsten Kobe, Georg Kuhnert, Andreas Lohri, Richard Greil, Stephanie Sasse, Max S Topp, Erhardt Schäfer, Bernd Hertenstein, Martin Soekler, Martin Vogelhuber, Josée M Zijlstra, Ulrich Bernd Keller, Stefan W Krause, Martin Wilhelm, Georg Maschmeyer, Julia Thiemer, Ulrich Dührsen, Julia Meissner, Andreas Viardot, Hans Eich, Christian Baues, Volker Diehl, Andreas Rosenwald, Bastian von Tresckow, Markus Dietlein, Peter Borchmann, Andreas Engert
PURPOSE: Combined-modality treatment (CMT) with 2× ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiotherapy is standard of care for patients with early-stage favorable Hodgkin lymphoma (HL). However, the role of radiotherapy has been challenged. Positron emission tomography (PET) after 2× ABVD (PET-2) might help to predict individual outcomes and guide treatment. METHODS: Between November 2009 and December 2015, we recruited patients age 18 to 75 years with newly diagnosed, early-stage favorable HL for this international randomized phase III trial...
September 10, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#13
Andreas Rosenwald, Susanne Bens, Ranjana Advani, Sharon Barrans, Christiane Copie-Bergman, Mad-Helenie Elsensohn, Yaso Natkunam, Maria Calaminici, Birgitta Sander, Maryse Baia, Alexandra Smith, Daniel Painter, Luu Pham, Shuchun Zhao, Marita Ziepert, Ekaterina S Jordanova, Thierry J Molina, Marie José Kersten, Eva Kimby, Wolfram Klapper, John Raemaekers, Norbert Schmitz, Fabrice Jardin, Wendy B C Stevens, Eva Hoster, Anton Hagenbeek, John G Gribben, Reiner Siebert, Randy D Gascoyne, David W Scott, Philippe Gaulard, Gilles Salles, Catherine Burton, Daphne de Jong, Laurie H Sehn, Delphine Maucort-Boulch
PURPOSE: MYC rearrangement ( MYC -R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis in many studies. The impact of MYC- R on prognosis may be influenced by the MYC partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated a large cohort of patients through the Lunenburg Lymphoma Biomarker Consortium to validate the prognostic significance of MYC-R (single-, double-, and triple-hit status) in DLBCL within the context of the MYC partner gene...
September 9, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#14
Meredith M Regan, Lillian Werner, Sumati Rao, Komal Gupte-Singh, F Stephen Hodi, John M Kirkwood, Harriet M Kluger, James Larkin, Michael A Postow, Corey Ritchings, Mario Sznol, Ahmad A Tarhini, Jedd D Wolchok, Michael B Atkins, David F McDermott
PURPOSE: Outcome measures that comprehensively capture attributes of immuno-oncology agents, including prolonged treatment-free time and persistent treatment-related adverse events (TRAEs), are needed to complement conventional survival end points. METHODS: We pooled data from the CheckMate 067 and 069 clinical trials of nivolumab and ipilimumab, as monotherapies or in combination, for patients with advanced melanoma. Treatment-free survival (TFS) was defined as the area between Kaplan-Meier curves for two conventional time-to-event end points, each defined from random assignment: time to immune checkpoint inhibitor (ICI) protocol therapy cessation and time to subsequent systemic therapy initiation or death...
September 9, 2019: Journal of Clinical Oncology
#15
Danielle S Bitterman, Shannon M MacDonald, Torunn I Yock, Nancy J Tarbell, Karen D Wright, Susan N Chi, Karen J Marcus, Daphne A Haas-Kogan
No abstract text is available yet for this article.
September 9, 2019: Journal of Clinical Oncology
#16
R Wendel Naumann, Antoine Hollebecque, Tim Meyer, Michael-John Devlin, Ana Oaknin, Joseph Kerger, Jose M López-Picazo, Jean-Pascal Machiels, Jean-Pierre Delord, Thomas R J Evans, Valentina Boni, Emiliano Calvo, Suzanne L Topalian, Tian Chen, Ibrahima Soumaoro, Bin Li, Junchen Gu, Ricardo Zwirtes, Kathleen N Moore
PURPOSE: Nivolumab was assessed in patients with virus-associated tumors in the phase I/II CheckMate 358 trial (ClinicalTrials.gov identifier: NCT02488759). We report on patients with recurrent/metastatic cervical, vaginal, or vulvar cancers. PATIENTS AND METHODS: Patients received nivolumab 240 mg every 2 weeks. Although patients with unknown human papillomavirus status were enrolled, patients known to have human papillomavirus-negative tumors were ineligible. The primary end point was objective response rate...
September 5, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#17
Channing J Paller, Mario A Eisenberger
No abstract text is available yet for this article.
September 4, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#18
Michael J Jelinek, Everett E Vokes
No abstract text is available yet for this article.
September 4, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#19
Kala Visvanathan, Carol J Fabian, Elissa Bantug, Abenaa M Brewster, Nancy E Davidson, Andrea DeCensi, Justin D Floyd, Judy E Garber, Erin W Hofstatter, Seema A Khan, Maria C Katapodi, Sandhya Pruthi, Rachal Raab, Carolyn D Runowicz, Mark R Somerfield
PURPOSE: To update the ASCO guideline on pharmacologic interventions for breast cancer risk reduction and provide guidance on clinical issues that arise when deciding to use endocrine therapy for breast cancer risk reduction. METHODS: An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS: A randomized clinical trial that evaluated the use of anastrozole for reduction of estrogen receptor-positive breast cancers in postmenopausal women at increased risk of developing breast cancer provided the predominant basis for the update...
September 3, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
#20
Phillip S Blanchette, Hannah Chung, Kathleen I Pritchard, Craig C Earle, Michael A Campitelli, Sarah A Buchan, Kevin L Schwartz, Natasha S Crowcroft, Jonathan B Gubbay, Timothy Karnauchow, Kevin Katz, Allison J McGeer, James D McNally, David C Richardson, Susan E Richardson, Laura C Rosella, Andrew Simor, Marek Smieja, George Zahariadis, Aaron Campigotto, Jeffrey C Kwong
PURPOSE: Seasonal influenza vaccination is recommended for patients with cancer despite concerns of disease or treatment-associated immunosuppression. The objective of this study was to evaluate vaccine effectiveness (VE) against laboratory-confirmed influenza for patients with cancer. PATIENTS AND METHODS: We conducted an observational test-negative design study of previously diagnosed patients with cancer 18 years of age and older who underwent influenza testing during the 2010-2011 to 2015-2016 influenza seasons in Ontario, Canada...
August 29, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Fetching more papers... 
